Genome Engineering via CRISPR-Cas9 System
Vijai Singh (Redaktør) ; Pawan K. Dhar (Redaktør)
Genome Engineering via CRISPR-Cas9 Systems presents a compilation of chapters from eminent scientists from across the globe
who have established expertise in working with CRISPR-Cas9 systems. Currently, targeted genome engineering is a key technology for basic science, biomedical and industrial applications due to the relative
simplicity to which they can be designed, used and applied. Les mer
- Vår pris
- 2279,-
(Paperback)
Fri frakt!
Leveringstid: Sendes innen 21 dager
På grunn av Brexit-tilpasninger og tiltak for å begrense covid-19 kan det dessverre oppstå forsinket levering
Vår pris:
2279,-
(Paperback)
Fri frakt!
Leveringstid: Sendes innen 21 dager
På grunn av Brexit-tilpasninger og tiltak for å begrense covid-19 kan det dessverre oppstå forsinket levering
Genome Engineering via CRISPR-Cas9 Systems presents a compilation of chapters from eminent scientists from across the globe
who have established expertise in working with CRISPR-Cas9 systems. Currently, targeted genome engineering is a key technology
for basic science, biomedical and industrial applications due to the relative simplicity to which they can be designed, used
and applied. However, it is not easy to find relevant information gathered in a single source. The book contains a wide range
of applications of CRISPR in research of bacteria, virus, algae, plant and mammalian and also discusses the modeling of drosophila,
zebra fish and protozoan, among others.
Other topics covered include diagnosis, sensor and therapeutic applications, as well as ethical and regulatory issues. This book is a valuable source not only for beginners in genome engineering, but also researchers, clinicians, stakeholders, policy makers, and practitioners interested in the potential of CRISPR-Cas9 in several fields.
Other topics covered include diagnosis, sensor and therapeutic applications, as well as ethical and regulatory issues. This book is a valuable source not only for beginners in genome engineering, but also researchers, clinicians, stakeholders, policy makers, and practitioners interested in the potential of CRISPR-Cas9 in several fields.